



US011752198B2

**(12) United States Patent**  
**Moeller et al.****(10) Patent No.: US 11,752,198 B2**  
**(45) Date of Patent: Sep. 12, 2023****(54) GLP-1 COMPOSITIONS AND USES THEREOF****(71) Applicant: Novo Nordisk A/S, Bagsvaerd (DK)****(72) Inventors: Eva Horn Moeller, Alleroed (DK); Michael Duelund Soerensen, Soeborg (DK); Joakim Lundqvist, Malmoe (SE)****(73) Assignee: Novo Nordisk A/S, Bagsvaerd (DK)****(\*) Notice:** Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.**(21) Appl. No.: 17/115,773****(22) Filed: Dec. 8, 2020****(65) Prior Publication Data**

US 2021/0085755 A1 Mar. 25, 2021

**Related U.S. Application Data****(63)** Continuation of application No. 16/774,666, filed on Jan. 28, 2020, now Pat. No. 10,888,605, which is a continuation of application No. PCT/EP2018/072835, filed on Aug. 24, 2018.**(30) Foreign Application Priority Data**

Aug. 24, 2017 (EP) ..... 17187676

**(51) Int. Cl.****A61K 38/26** (2006.01)**A61K 9/00** (2006.01)**A61K 9/08** (2006.01)**A61K 47/02** (2006.01)**A61K 47/10** (2017.01)**(52) U.S. Cl.**CPC ..... **A61K 38/26** (2013.01); **A61K 9/0019** (2013.01); **A61K 9/08** (2013.01); **A61K 47/02** (2013.01); **A61K 47/10** (2013.01)**(58) Field of Classification Search**CPC ..... **A61K 38/26**; **A61K 9/0019**; **A61K 47/10**; **A61K 9/08**; **A61K 47/02**

See application file for complete search history.

**(56) References Cited****U.S. PATENT DOCUMENTS**2,444,570 A 8/1946 Lawrence et al.  
2,828,742 A 4/1958 Ashkenaz  
3,318,289 A 5/1967 Marynissen  
3,758,683 A 9/1973 Jackson  
4,282,316 A 8/1981 Modrovich  
4,425,346 A 1/1984 Horlington  
4,468,346 A 8/1984 Paul et al.  
4,470,317 A 9/1984 Sabloewski et al.  
4,483,849 A 11/1984 Carter et al.  
4,498,904 A 2/1985 Turner et al.  
4,568,335 A 2/1986 Updike et al.  
4,585,439 A 4/1986 Michel  
4,592,745 A 6/1986 Rex et al.  
4,629,455 A 12/1986 Kanno4,833,379 A 5/1989 Kaibel et al.  
4,865,591 A 9/1989 Sams  
4,883,472 A 11/1989 Michel  
4,917,685 A 4/1990 Viswanathan et al.  
4,919,596 A 4/1990 Slate et al.  
4,936,833 A 6/1990 Sams  
4,973,318 A 11/1990 Holm et al.  
4,994,033 A 2/1991 Shockey et al.  
5,017,190 A 5/1991 Simon et al.  
5,092,842 A 3/1992 Bechtold et al.  
5,112,317 A 5/1992 Michel  
5,114,406 A 5/1992 Gabriel et al.  
5,118,666 A 6/1992 Habener  
5,120,712 A 6/1992 Habener  
5,169,759 A 12/1992 Faust et al.  
5,169,771 A 12/1992 Christner et al.  
5,206,216 A 4/1993 Yoshida  
5,206,219 A 4/1993 Desai  
5,207,752 A 5/1993 Sorenson et al.  
5,216,011 A 6/1993 Paborji et al.  
5,216,437 A 6/1993 Yamamoto et al.  
5,226,895 A 7/1993 Harris  
5,232,459 A 8/1993 Hjertman  
5,232,706 A 8/1993 Palomo Coll  
5,246,417 A 9/1993 Haak et al.  
5,257,987 A 11/1993 Athayde et al.  
5,271,527 A 12/1993 Haber et al.  
5,272,135 A 12/1993 Takruri  
5,279,585 A 1/1994 Balkwill

(Continued)

**FOREIGN PATENT DOCUMENTS**AU 611385 B2 6/1991  
CA 2223531 A1 12/1996

(Continued)

**OTHER PUBLICATIONS**BASF: "BASF Chemical Emergency Medical Guidelines," Jan. 1, 2016, Retrieved from the Internet: URL: [https://www.basf.com/documents/corp/en/sustainability/employees-and-society/employees/occupational-medicine/medical-guidelines/PhenoL\\_B\\_BASF\\_medGuidelines\\_E104.pdf](https://www.basf.com/documents/corp/en/sustainability/employees-and-society/employees/occupational-medicine/medical-guidelines/PhenoL_B_BASF_medGuidelines_E104.pdf), retrieved on Nov. 20, 2017.

Lau et al., Journal of Medicinal Chemistry, 2015, vol. 58, No. 18, pp. 7370-7380.

Marbury et al., "Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Once-Weekly Human GLP-1 Analogue, in Subjects With and Without Renal Impairment," Diabetologia, 2014, vol. 57, Supplement: 1, pages S358-S359.

The report excerpts including some chromatograms from patent ZL200480034152.8, granted Feb. 25, 2015.

Pharmacopoeia of China 2000 Edition, Chemical Industry Press, vol. 2, pp. 378-381, Apr. 2001.

Pharmacopoeia of China 2000 Edition, Chemical Industry Press, vol. 2, p. 94, Jan. 2000.

Pharmaceutics, Edition 4, People's Health Publishing House, pp. 198-199 and 240, Jul. 2002.

(Continued)

*Primary Examiner* — Sudhakar Katakam**(74) Attorney, Agent, or Firm** — Rosemarie R. Wilk-Orescan**(57) ABSTRACT**

The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising no more than 0.01% (w/w) phenol, their preparation, kits comprising such compositions as well as uses thereof.

**9 Claims, No Drawings**